In a review of nearly 200,000 patients from a Midwest metropolitan area, researchers sought to determine if chronic aspirin use would offer the same risk reduction for melanoma as has been seen in various cancers.
A cross-sectional analysis evaluated the impact of hope and optimism on different facets of psychological distress among patients with advanced melanoma, colorectal, lung, or gastrointestinal cancers.
Investigators sought to compare the prognostic value of sentinel lymph node status vs Breslow thickness in patients with cutaneous melanoma.
The likelihood for development of cutaneous melanoma may be greater for individuals with iris pigmented lesions, according to a study.
Investigators sought to evaluate whether age is associated with risk for immune-related adverse events among patients with metastatic melanoma treated with immunotherapy.
Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.
iPSC vaccine prevented tumor growth in syngeneic murine breast CA, mesothelioma, melanoma models
A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.
The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.
Melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.
Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.
Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months in the last decade.
Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.
Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care Providers
Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
When researchers sent sample slides to pathologists for review, the assessments varied widely and some pathologists even disagreed with their own initial assessment when retested months later.
Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.
Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
'Conquer Fear' decreased fear among survivors of breast and colorectal cancer and melanoma compared with relaxation techniques.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.
Dermatologist assessment of screening practices addresses the lack of a national consensus on screening guidelines for melanoma.
Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.
Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.
Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.
Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.
Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.
Researchers sought to conduct a cost-effectiveness analysis of immunotherapy for patients with advanced melanoma.
Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
Using statistical models, predictions were made for death rates from melanoma in 3 three countries and based on availability of a treatment.
Researchers compared the ability of an artificial-intelligence algorithm to recognize and classify skin cancers with the clinical evaluations of dermatologists.
Induction therapy with intravenous interferon α-2b appeared to be no better than observation alone for the management of patients with intermediate-risk melanoma.
Results of a series of Internet surveys revealed customers' perceptions of harms, benefits, and limitations of genetic information received from direct-to-consumer genetic testing.
Comparison studied the effectiveness of sun protection offered by a beach umbrella alone with that of sunscreen with a high sun protection factor.
Melanoma incidence varies by region, and many states have experienced an increase.
A review of data from three large, prospective studies examined a potential association between alcoholic beverage consumption and risk of melanoma.
Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.
Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.
Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.
More melanomas are self-detected by women; men tend to have more melanomas in less visible locations.
A newly developed, evidence-based psychoeducational intervention effectively reduced fear of cancer recurrence and stress in patients at high risk for developing another melanoma.
Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.
Pevonedistat was effective for inhibiting proliferation of melanoma cell lines in vitro, research indicates.
Patients with localized melanoma see their supportive care needs peak at their initial cancer diagnosis and if they experience disease recurrence.
Response rates with PD-1 inhibitors in patients with acral and mucosal melanomas were similar to previously reported rates in patients with cutaneous melanoma.
Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.
Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.
New report doesn't change Task Force's prior statement on skin cancer screening issued in 2009
Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries
Training primary care providers (PCP) to detect early melanoma led to increased melanoma diagnoses, but had little impact on skin surgeries or dermatology visits.
The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care
[Cancer Informatics] In this research, a microsimulation model framework is used to examine the impact of simultaneously altering curative treatment approaches in different phases of melanoma treatment.
Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.
De novo melanomas, which arise from clinically normal skin with no associated nevus, may be more aggressive than nevus-associated melanomas.
In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.
Population-based screening for melanoma performed by primary care providers does not cause substantial harm with respect to skin surgeries and dermatology visits.
PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.
Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic Melanoma
A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.
Cutaneous melanoma is rare on feet, but often advanced at point of diagnosis.
Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 ASCO Annual Meeting has shown.
A newly discovered synthesized drug reduced the viability of melanoma cells without affecting normal cells in cell culture and mouse xenograft models of the disease. The drug, HA15, is a type of thiazole benzenesulfonamide.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.
Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.
Combining radiation treatments with a new generation of immunotherapies is showing promise in the treatment of melanoma, according to a recent review.
Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.
Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.
The Bim protein might predict which patients could be successfully treated with immunotherapy for metastatic melanoma.
New study highlights the importance of diagnosing and treating obstructive sleep apnea because of possible cancer connection.
[Cancer Control] This research explores the efficacy of intralesional therapy as a treatment option for patients with unresectable, locally advanced, or metastatic melanoma.
Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.
Melanoma onset was delayed by applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B light in a mouse model of the disease.
Among patients with advanced melanoma, the human PD-1-blocking antibody pembrolizumab was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months.
Therapy for the elderly with melanoma may be affected by findings that aged tumor cells in melanoma behave differently than younger tumor cells.
Though sunbathers are at an increased risk of developing skin cancer, women who sunbathe are likely to live longer than those who avoid the sun.
Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.
Variant of gene linked to skin pigmentation may be tied to higher melanoma risk.
Physicians shouldn't rely on mole count as the only reason to perform skin exams for melanoma.
The expression of the PAX3 and MITF genes in melanoma can cause early, nonmutational, reversible drug resistance; tissues that express these genes can then later develop mutational, irreversible drug resistance. The HIV drug nelfinavir can prevent this resistance.
Among women aged up to 49 years with a pregnancy-associated melanoma, recurrence rates were higher than seen in other groups.
Anti-programmed cell death-1 therapy tied to lichenoid reactions, eczema, vitiligo
A new biomarker measurement might improve the accuracy of prognostic testing and precision medicine in uveal melanoma.
RECIST v1.1 may underestimate the treatment response in patients with advanced melanoma treated with pembrolizumab.
Among younger patients, thick melanomas may be commonly found in those with fewer total nevi but more atypical nevi.
PRAME mRNA expression is independent prognostic biomarker in Class 1 uveal melanoma.
Researchers visualized the origins of cancer from the first affected cell through its spread in a live animal: the zebrafish. This research may change scientific understanding of melanoma and other cancers leading to new treatments that can be administered before the cancer has taken hold.
No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.
Patients with advanced cancer view life goals as distinct from and less important than treatment goals, according to a recent study.
Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis
Younger age at first use and more frequent use of indoor tanning beds are largely responsible for the steep increase in melanoma diagnoses in women younger than 40 years.
Prognosis for patients with cutaneous melanoma may be predicted by an inherited genetic marker providing a personalized tool to gauge a person's survival and determine if closer monitoring is needed in the years following surgery.
A recent study showed that women younger than 50 years who are pregnant or were recently pregnant at diagnosis of melanoma have a higher risk of death from the skin cancer.
Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with melanoma.
Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|